N. Bucay, I. Sarosi, I. , C. R. Dunstan, S. Morony et al., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev, vol.12, pp.1260-1268, 1998.

K. Mori, B. L. Goff, B. , C. Charrier, S. Battaglia et al., DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process, Bone, vol.40, pp.981-990, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00667539

M. Baud'huin, L. Duplomb, S. Télétchéa, C. Charrier, M. Maillasson et al., Factor VIII-von Willebrand Factor complex inhibits osteoclastogenesis and controls cell survival, J Biol. Chem, vol.284, pp.31704-31713, 2009.

I. Holen and C. M. Shipman, Role of osteoprotegerin (OPG) in cancer, Clin. Sci, vol.110, pp.279-291, 2006.

E. Corey, L. G. Brown, J. A. Kiefer, J. E. Quinn, T. E. Pitts et al., Osteoprotegerin in prostate cancer bone metastasis, Cancer Res, vol.65, pp.1710-1718, 2005.

B. D. Ragland, W. C. Bell, and R. R. Lopez, Cytogenetics and molecular biology of osteosarcoma, Lab. Invest, vol.82, pp.365-373, 2002.

O. N. Vidal, K. Sjögren, B. I. Eriksson, O. Ljunggren, and C. Ohlsson, Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells, Biochem. Biophys. Res. Commun, vol.248, pp.696-700, 1998.

F. Lamoureux, G. Picarda, L. Garrigue-antar, M. Baud'huin, V. Trichet et al., Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma, Cancer Res, vol.69, pp.526-536, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01680055

J. L. Fisher, R. J. Thomas-mudge, J. Elliott, D. K. Hards, and N. A. Sims, Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically, Cancer Res, vol.66, pp.3620-3628, 2006.

I. Holen, P. I. Croucher, F. C. Hamdy, and C. L. Eaton, Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells, Cancer Res, vol.62, pp.1619-1623, 2002.

K. Jung, M. Lein, C. Stephan, K. Von-höslin, A. Semjonow et al., Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications, Int. J. Cancer, vol.111, pp.783-791, 2004.

M. G. Alexandrakis, A. Sfiridaki, S. Miyakis, C. Pappa, E. Kindidaki et al., Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma, Clin. Chim. Acta, vol.379, pp.31-35, 2007.

S. C. Gupta, J. H. Kim, S. Prasad, and B. Aggarwal, Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals, Cancer Metastasis Rev, vol.29, pp.405-434, 2010.

L. N. Pritzker, M. Scatena, and C. M. Giachelli, The Role of Osteoprotegerin and Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Human Microvascular Endothelial Cell Survival, Mol. Biol. Cell, vol.15, pp.2834-2841, 2004.

Z. Benslimane-ahmim, D. Heymann, B. Dizier, A. Lokajcyk, R. Brion et al., Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colonyforming cells properties, J. Thromb. Haemost, vol.9, pp.834-843, 2011.

E. Chavakis, C. Urbich, and S. Dimmeler, Homing and engraftment of progenitor cells: a prerequisite for cell therapy, J. Mol. Cell Cardiol, vol.45, pp.514-522, 2008.

B. Janic and A. S. Arbab, The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization, ScientificWorldJournal, vol.10, pp.1088-1099, 2010.

S. Liekens, D. Schols, and S. Hatse, CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization, Curr. Pharm. Des, vol.16, pp.3903-3920, 2010.

T. Ibrahim, E. Sacanna, M. Gaudio, L. Mercatalli, E. Scarpi et al., Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients, Clin. Breast Cancer, vol.11, pp.369-375, 2011.

F. Zemani, D. Benisvy, I. Galy-fauroux, A. Lokajczyk, A. et al., Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells, Biochem. Pharmacol, vol.70, pp.1167-1175, 2005.

B. Uygur and W. S. Wu, SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis, Mol. Cancer, vol.10, p.139, 2011.

H. Penno, On the role of Osteoprotegerin/RANK/RANKL system in the interaction between prostate cancer and bone, Digital comprehensive Summaries of Uppsala Dissertations, 2011.

K. Chandramohan, T. Somanathan, P. Kusumakumary, P. G. Balagopal, and M. Pandey, Metastatic osteosarcoma causing intussusception, J. Pediatr. Surg, vol.38, pp.1-3, 2003.

Z. Benslimane-ahmim, F. Poirier, C. Delomiene, A. Lokajszyk, F. Grelac et al., Mechanistic study of the proangiogenic effect of osteoprotegerin, Angiogenesis, vol.16, pp.575-593, 2013.

W. C. Dougall, Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis, Clin. Cancer Res, vol.18, pp.326-335, 2012.

J. Posthumadeboer, M. A. Witlox, G. J. Kaspers, and B. J. Van-royen, Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature, Clin. Exp. Metastasis, vol.28, pp.493-503, 2011.

M. L. Broadhead, J. C. Clark, D. E. Myers, C. R. Dass, and P. F. Choong, The molecular pathogenesis of osteosarcoma: a review, Sarcoma, p.959248, 2011.

E. Perissinotto, G. Cavalloni, F. Leone, V. Fonsato, S. Mitola et al., Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression, Clin. Cancer Res, vol.11, pp.490-497, 2005.

Y. Oda, H. Yamamoto, S. Tamiya, S. Matsuda, K. Tanaka et al., CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis, Mod. Pathol, vol.19, pp.738-745, 2006.

I. M. Bennani-baiti, A. Cooper, E. R. Lawlor, M. Kauer, J. Ban et al., Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma, Clin. Cancer Res, vol.16, pp.3769-3778, 2010.

H. M. Namlos, S. H. Kresse, C. R. Müller, J. Henriksen, R. Holdhu et al., Global gene expression profiling of human osteosarcomas reveals metastasisassociated chemokine pattern, Sarcoma, vol.2012, p.639038, 2012.

R. Ito and H. Nakayama,

K. Yoshida, K. Kuraoka, J. Motoshida, and N. Oda, Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma, Virchows Archiv, vol.443, pp.146-151, 2003.

J. Folkman, Angiogenesis. Annu. Rev. Med, vol.57, pp.1-18, 2006.

S. S. Cross, Z. Yang, N. J. Brown, S. P. Balasubramanian, C. A. Evans et al., Osteoprotegerin (OPG)-a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?, Int. J. Cancer, vol.118, pp.1901-1908, 2006.